Related Experiment Video
Updated: Jul 17, 2026
Robotic Duodenum-preserving Total Pancreatic Head Resection for Intraductal Papillary Mucinous Neoplasms
Published on: April 17, 2026
Solid pseudopapillary neoplasm of the pancreas: A retrospective single-center cohort study of 1,058 consecutive
Yi Liu1, Nuoyan Zhang1, Yilin Song1
1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China; Shanghai Key Laboratory of Precision Medicine for Pancreatic Cancer, Shanghai, 200032, China; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China.
Background:
Solid pseudopapillary neoplasm (SPN) of the pancreas is a rare, low-grade malignant tumor, predominantly affecting young women. Although the overall prognosis of SPN is good, the understanding of its pathophysiological characteristics and the selection of treatment strategies remain insufficient.
Methods:
A retrospective analysis of 1058 consecutive patients with pathologically confirmed SPN was performed at a single institution. Clinicopathological characteristics, immunohistochemical profiles, targeted sequencing data, and overall survival were systematically evaluated.
Results:
The median age of the patients at diagnosis was 33 years, with females being the majority (78.1%). Most tumors were located in the body/tail (70.2%), larger than 3 cm (61.9%), while invasive features such as vascular invasion (1.6%), nerve invasion (7.0%), and lymph node metastasis (0.7%) were rare. Early-stage (stage I, II) patients were more common (99.1%). In recent years, the surgical procedures have significantly shifted towards minimally invasive and parenchyma-sparing surgery. The prognosis of SPN was excellent, with a 5-year survival of 97.9%. Molecular analysis revealed nearly universal CTNNB1 mutations (97%). High expression of progesterone receptor (PR, 97.2%) and low expression of estrogen receptor (ER, 7.7%) supported hormone dependence.
Conclusions:
This large single-center cohort study confirms that SPN is a tumor with low malignant potential, and identifies the key clinicopathological and molecular factors associated with malignant features. Different hormone receptor profiles provide a theoretical basis for exploring hormone receptor-targeted therapy for advanced patients.
